Latest News and Press Releases
Want to stay updated on the latest news?
Search Results
Everything
-
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
-
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
-
Simpson Associates announces a partnership with The Sovini Group to implement Microsoft’s Fabric Platform, starting with our Proof of Concept.
-
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
-
Read our Press Release on how Simpson Associates have teamed up with Assosia to precisely product match using Machine Learning.
-
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
-
—Readily formed Li2CO3 is 99.91% pure VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a...
-
VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a multi-faceted mineral explorer and joint venture...
-
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...
-
HIGHLIGHTS >99.9% purity lithium carbonate produced (aka ‘3 nines’)Successful proof-of-concept of modern lithium processing technologyStart-to-finish direct extraction of lithium from brine in...